FDA Approves Broadened Indication for XEOMIN® (IncobotulinumtoxinA) as First-Line Treatment for Blepharospasm (Involuntary Blinking) in Adult Patients

Patients were defined as treatment-nave if at least 12 months had passed since their last toxin treatment.